Application

Apolipoprotein C-II activates lipoprotein lipase and has been used in a study to assess HDL proteome in hemodialysis patients. An excess of apolipoprotein C-II is associated with increased triglyceride-rich particles and alterations in HDL particle distribution.

Biochem/physiol Actions

Apolipoprotein C2 (APOC2) serves as an activator of lipoprotein lipase. It is involved in the hydrolysis of triglycerides (TG) on TG-rich lipoproteins (TRL) to release free fatty acids (FA). Higher expression of APOC2 is observed in patient-derived glioblastoma stem cells, hypopharyngeal cancer, invasive ductal breast cancer, clear cell renal cell carcinoma, gastric cancer, centroblastic lymphoma, early-stage colorectal tumor, and skin squamous cell carcinoma. ApoC-2 is considered as a new sensitive biomarker for diagnosing Takayasu arteritis (TAK).

Activates lipoprotein lipase

General description

Apolipoprotein C-II (APOC2/apoC-II), a small exchangeable apolipoprotein, is expressed in the liver and secreted into plasma. It is present on the triglyceride-rich lipoproteins (TRL), like chylomicrons (CM) and very-low-density lipoproteins (VLDL), and high-density lipoproteins (HDL), mainly during fasting. The intestine, macrophages, adipose tissue, brain, skin, lungs, retina, and retinal pigment epithelium are among the tissues that produce ApoC-II.